© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
Administration Anounces Landmark GLP-1 Pricing Agreement with Eli Lilly and Novo Nordisk
November 06, 2025
Trump announces deals with Eli Lilly and Novo Nordisk slashing GLP-1 prices to as low as $150/month, expanding Medicare coverage starting mid-2026.
Oral Semaglutide 25 mg Shows Cardiometabolic Benefits Beyond Weight Loss in OASIS 4 Analysis
November 06, 2025
Oral semaglutide 25 mg improved glucose control and CV risk factors across weight loss categories in OASIS 4 post hoc analysis presented at ObesityWeek 2025.
Precision Medicine Protocol for Cognitive Decline May Also Reduce Depression: Daily Dose
November 06, 2025
Your daily dose of the clinical news you may have missed.
Lumateperone Gets FDA Nod as Adjunctive Therapy for Major Depressive Disorder
November 06, 2025
As adjunctive treatment, lumateperone is associated with early symptom improvement, good tolerability, and provides a practical no-titration option for adults with persistent MDD.
Wegovy Users More Likely to Reach Key Obesity Treatment Targets, STEP UP Study Finds
November 06, 2025
Novo Nordisk’s STEP UP trial shows semaglutide delivers 21% weight loss and reduces key cardiovascular and metabolic risk factors in obesity management.
Moderate-to-Severe OSA Linked to Doubled Risk of Brain Microbleeds Over 8 Years: New Research
November 06, 2025
New longitudinal data from a Korean cohort suggest OSA may be an independent risk factor for cerebral small vessel disease.
5 Novel Mechanisms Reshaping Atopic Dermatitis Treatment and the Phase 2-3 Clinical Trials That Support Them
November 06, 2025
Novel AD therapies targeting OX40, IL-13, IL-36, IL-22, and IL-2 pathways show promise for disease modification and extended dosing intervals in phase 2-3 trials.
The Hidden Toll of Diabetes in the Workplace: Global Survey Data
November 05, 2025
Global survey data highlight persistent stigma and self-management barriers for adults with diabetes in the workplace, with implications for clinical care.
FDA Approves Simplified Once-Monthly Mirikizumab-mrkz Regimen for Ulcerative Colitis Maintenance Therapy
November 05, 2025
The FDA approves a single monthly injection of mirikizumab-mrkz for ulcerative colitis, enhancing patient convenience and addressing bowel urgency effectively.
Complementary Studies Point to How to Boost CRC Screening Rates
November 05, 2025
Patient preferences favor home-based tests but MDs do not, while cost barriers significantly impact follow-up completion, according to the 2 new analyses.